Table 4

Pooled weighted responder proportion for all treatments reported in at least one other study with five or more participants

TreatmentEntityRespondersTotalPooled weighted responder proportion
(95% CI)
Heterogeneity
(I2)
Preventative treatments
LamotrigineSUNHA1182160.56 (0.49 to 0.63)49%
SUNCT801370.59 (0.50 to 0.68)47%
SUNA38760.50 (0.38 to 0.62)64%
CarbamazepineSUNHA431580.26 (0.19 to 0.34)0%
SUNCT23870.26 (0.17 to 0.36)80%
SUNA19630.30 (0.19 to 0.42)25%
GabapentinSUNHA351430.22 (0.15 to 0.30)93%
SUNCT24870.26 (0.17 to 0.36)94%
SUNA10480.19 (0.02 to 0.32)81%
TopiramateSUNHA341210.27 (0.19 to 0.36)28%
SUNCT29750.39 (0.28 to 0.50)35%
SUNA4400.09 (0.01 to 0.21)0%
PregabalinSUNHA9890.10 (0.04 to 0.17)0%
SUNCT5440.10 (0.02 to 0.22)0%
SUNA4450.09 (0.02 to 0.19)0%
OxcarbazepineSUNHA30760.38 (0.27 to 0.50)87%
SUNCT14360.38 (0.22 to 0.56)51%
SUNA16400.37 (0.22 to 0.54)86%
Transitional treatments
Parenteral lidocaineSUNHA89960.94 (0.88 to 0.98)9%
SUNCT58620.95 (0.87 to 1.00)0%
SUNA31350.91 (0.77 to 1.00)0%
Greater occipital nerve blockadeSUNHA30940.31 (0.22 to 0.41)79%
SUNCT17590.28 (0.17 to 0.41)66%
SUNA13350.36 (0.19 to 0.54)58%
  • SUNA, short-lasting unilateral neuralgiform headache attacks with autonomic symptoms; SUNCT, short-lasting unilateral neuralgiform attacks with conjunctival injection and tearing; SUNHA, short-lasting unilateral neuralgiform headache attacks.